Cartalax Peptide 20mg

Description

What Is Cartalax Peptide?

Cartalax peptide is a synthetic tripeptide bioregulator with the amino acid sequence Ala-Glu-Asp (AED), developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Cartalax targets cartilage and connective tissue, functioning as a cartilage bioregulator that modulates gene expression in chondrocytes, fibroblasts, and supporting musculoskeletal matrix tissue. It belongs to the Khavinson bioregulator peptides class — short regulatory peptides that exhibit tissue-specific gene expression modulation at physiological concentrations — and has been studied in preclinical models of cartilage aging, tissue repair, chronic joint inflammation, and age-related musculoskeletal decline.

Cartilage is among the most difficult tissues to regenerate in the adult body. Unlike vascularized tissues that benefit from blood-borne growth factors and immune cells, cartilage is avascular and relies almost entirely on the synthetic capacity of resident chondrocytes for maintenance and repair. As chondrocyte function declines with age, cartilage deterioration becomes progressive and largely irreversible under normal conditions. Cartalax addresses this fundamental challenge by operating at the gene expression level in chondrocytes, modulating the transcriptional programs that govern matrix synthesis, chondrocyte survival, and tissue homeostasis. Among all Khavinson bioregulators, cartalax is the dedicated cartilage peptide bioregulator and the primary compound for musculoskeletal aging research. PrymaLab Cartalax 20mg is manufactured to high purity standards and supplied exclusively for qualified preclinical research.

Cartalax 20mg: Key Specifications

How Does Cartalax Peptide Work?

Epigenetic Gene Expression Modulation in Cartilage Tissue

Cartalax operates through the peptide-DNA interaction mechanism described by Professor Khavinson’s research group, wherein the AED tripeptide sequence selectively binds specific DNA motifs within gene promoter regions of cartilage cells and modulates chromatin conformation. In chondrocytes and connective tissue fibroblasts, cartalax influences the expression of genes governing extracellular matrix synthesis, proteoglycan production, collagen assembly, and chondrocyte differentiation. This epigenetic mechanism operates at physiologically relevant concentrations, distinguishing bioregulator peptides from pharmacological agents that target downstream inflammatory or catabolic pathways.

Chondrocyte Function and Matrix Homeostasis

Cartilage homeostasis depends entirely on the balance between matrix synthesis and degradation by resident chondrocytes. During aging, this balance shifts toward catabolism as chondrocytes reduce production of type II collagen, aggrecan, and other matrix components while upregulating matrix metalloproteinases (MMPs). Cartalax research targets this imbalance at its transcriptional origin, modulating the genes that control the synthesis-degradation ratio in cartilage tissue. By restoring anabolic gene expression in aged chondrocytes, cartalax provides a research approach to cartilage preservation that addresses root causes rather than symptoms.

Connective Tissue Specificity

The tissue specificity of cartalax peptide derives from the selective affinity of the AED sequence for regulatory DNA motifs enriched in cartilage and connective tissue gene promoters. Preclinical studies have demonstrated that cartalax preferentially modulates gene expression in chondrocytes and musculoskeletal fibroblasts, with its effects concentrated in the genes governing extracellular matrix composition, structural protein assembly, and tissue mechanical properties.

Cartalax Peptide Benefits Reported in Preclinical Research

Published studies on cartalax peptide benefits report multiple cartilage-specific and connective tissue effects relevant to musculoskeletal aging research. All findings described below are from preclinical animal and cell culture models.

Cartilage Matrix Restoration

The most significant cartalax peptide benefit documented in the literature is the restoration of cartilage matrix synthesis in aged chondrocyte models. Studies demonstrate enhanced type II collagen gene expression, increased aggrecan production, improved proteoglycan content, and normalized glycosaminoglycan deposition in cartilage tissue treated with cartalax. These matrix restoration effects directly address the fundamental deficit in aged cartilage — reduced synthetic capacity of resident chondrocytes — and represent a gene-expression-level approach to cartilage preservation.

Anti-Inflammatory Effects in Joint Tissue

Chronic low-grade joint inflammation accelerates cartilage degradation and drives the progression of age-related joint disease. Among the documented cartalax benefits, suppression of pro-inflammatory gene expression in cartilage and synovial tissue has been consistently reported. Studies show reduced NF-κB pathway activation, decreased IL-1β and TNF-α expression in chondrocytes, and modulated MMP gene expression. These anti-inflammatory effects distinguish cartalax from conventional anti-inflammatory agents by targeting the transcriptional programs that sustain chronic joint inflammation rather than acutely suppressing individual mediators.

Chondrocyte Survival and Anti-Apoptotic Effects

Chondrocyte loss through apoptosis is a critical and largely irreversible event in cartilage aging. Cartalax research reports enhanced chondrocyte survival in aged and stress-exposed cartilage models, with upregulation of anti-apoptotic gene expression and improved cellular stress resistance. Given the extremely limited capacity for chondrocyte replacement in adult cartilage, these pro-survival effects have particular significance for research into cartilage longevity and preservation.

Tissue Repair and Regenerative Signaling

Beyond maintaining existing cartilage, cartalax research has documented modulation of regenerative signaling pathways in connective tissue, including enhanced expression of growth factor genes (TGF-β superfamily members, BMPs) and improved chondrocyte proliferative capacity in repair models. These tissue repair bioregulator effects extend cartalax’s research relevance into regenerative medicine applications for cartilage and connective tissue repair.

Musculoskeletal Anti-Aging Effects

Longitudinal studies by the Khavinson group have reported that cartalax administration is associated with preserved joint function, maintained cartilage thickness, and reduced histological signs of cartilage aging in chronically treated animal cohorts compared to controls. These musculoskeletal anti-aging observations support the broader bioregulatory hypothesis that tissue-specific gene expression modulation can slow the trajectory of cartilage degeneration during aging.

Cartalax Peptide Dosage in Research Applications

Published research provides context for cartalax peptide dosage parameters across different experimental paradigms. The following represents reported dosage ranges from preclinical literature and is intended solely to inform research protocol design.

Important: These are reported research dosages from published preclinical literature. Optimal cartalax dosage depends on experimental design, animal model, route of administration, and research objectives. This product is not intended for therapeutic use.

Cartalax in the Khavinson Bioregulator System: Musculoskeletal Context

Among the Khavinson bioregulators, cartalax occupies a unique position as the sole cartilage and connective tissue bioregulator. While other peptides in the system target organs with significant cellular turnover (liver, immune system, respiratory epithelium), cartalax addresses one of the body’s most repair-resistant tissues. This distinction makes cartalax particularly valuable for research into why cartilage ages differently from other tissues and whether epigenetic interventions can overcome the inherent regenerative limitations of avascular connective tissue.

For comprehensive musculoskeletal aging research, cartalax may be combined with bioregulators that address supporting systems: vesilute for vascular supply to joint tissues, vilon for systemic immune modulation affecting inflammatory joint processes, and organ-specific bioregulators for any co-morbid aging conditions under investigation.

How to Store and Handle PrymaLab Cartalax 20mg

1. Store lyophilized at −20°C. Keep sealed, desiccated, and protected from light. Stable for 24+ months.
2. Allow vial to reach room temperature before opening to prevent condensation.
3. Reconstitute with appropriate sterile solvent. Add slowly along vial wall.
4. Use reconstituted solution within 2–4 weeks. Refrigerate at 2–8°C.
5. Avoid repeated freeze-thaw cycles. Aliquot into single-use portions.
6. Retain the Certificate of Analysis for lot traceability.

Why Choose PrymaLab Cartalax 20mg?

PrymaLab supplies Cartalax 20mg as a high-purity research-grade cartilage bioregulator peptide verified at ≥98% purity by reverse-phase HPLC and identity-confirmed by mass spectrometry. Each batch ships with a unique lot number and Certificate of Analysis. Independent third-party testing ensures unbiased quality verification and full traceability for GLP-compliant musculoskeletal and aging research.

Frequently Asked Questions About Cartalax Peptide

What is cartalax peptide and what does it target?

Cartalax is a synthetic tripeptide bioregulator (Ala-Glu-Asp, AED) developed by Professor Khavinson targeting cartilage and connective tissue. It modulates gene expression in chondrocytes, fibroblasts, and musculoskeletal matrix tissue. Research applications include cartilage aging, joint inflammation, tissue repair, and musculoskeletal anti-aging in preclinical models.

What are the reported cartalax peptide benefits in research?

Published preclinical research reports cartalax peptide benefits including restored cartilage matrix synthesis (type II collagen, aggrecan, proteoglycans), anti-inflammatory gene modulation in joint tissue (reduced NF-κB, IL-1β, TNF-α, MMP expression), enhanced chondrocyte survival through anti-apoptotic signaling, improved regenerative gene expression (TGF-β, BMP pathways), and preserved joint function in longitudinal aging models. All benefits are from preclinical research.

How does cartalax differ from conventional joint supplements?

Cartalax operates through epigenetic gene expression modulation in chondrocytes rather than providing substrate supplementation (like glucosamine or chondroitin) or acute anti-inflammatory activity (like NSAIDs). It targets the transcriptional programs governing cartilage matrix synthesis and chondrocyte function, addressing the root epigenetic causes of cartilage aging rather than downstream symptoms or substrate deficiencies.

What is the recommended cartalax peptide dosage for research?

Published cartalax peptide dosage ranges include 10–200 nM for cell culture studies and 1–10 µg/kg for in vivo cartilage aging models. Dosing depends on experimental design, model system, and research objectives. This product is for preclinical research only and is not intended for therapeutic dosing.

How should cartalax be stored?

Store lyophilized cartalax at −20°C, desiccated and protected from light, for 24+ months stability. After reconstitution, store at 2–8°C and use within 2–4 weeks. Aliquot to avoid freeze-thaw cycles.

Research Disclaimer

For Research Use Only. PrymaLab Cartalax 20mg is intended exclusively for qualified preclinical research use. This product is not intended for human consumption, therapeutic use, veterinary treatment, or any application outside controlled research environments. Cartalax has not been approved by the FDA or any equivalent regulatory authority for therapeutic use. All research applications described are from published preclinical and gerontological literature. Researchers are responsible for regulatory compliance.